Clinical Chorioamnionitis at 24–34 Weeks: What to Do When Maternal Fever Presents with Two or More Clinical Signs
This protocol covers the evidence-based management of clinical chorioamnionitis diagnosed at a gestational age of 24 0/7 to 33 6/7 weeks — a preterm window where fetal considerations add to the complexity of acute infection management.
Clinical Scenario
The diagnosis is established by the presence of maternal fever together with two or more of the following signs:
- Maternal tachycardia
- Fetal tachycardia
- Uterine tenderness
- Purulent or foul-smelling amniotic fluid or vaginal discharge
- Maternal leukocytosis
Gestational age 24 0/7 – 33 6/7 weeks. At this preterm stage, the clinical picture requires attention not only to infection control but also to fetal lung maturation and neuroprotection — both of which are integral to the management plan.
Treatment Approach
Management involves prompt IV antibiotic therapy combined with antipyretic support. At this gestational age, antenatal interventions targeting fetal lung maturation and fetal neuroprotection are also incorporated into the regimen. Importantly, delivery is an active consideration from the moment the diagnosis is confirmed — it should not be deferred to await completion of adjunctive fetal therapies. The full protocol specifies the agents, sequencing, and delivery guidance.
Treatment Goals
Resolution of clinical chorioamnionitis within 16 hours of treatment initiation; reduction of maternal temperature and resolution of fetal tachycardia following antipyretic administration.
References
DOI: 10.1016/j.ajog.2020.09.044
Clinical chorioamnionitis has been traditionally diagnosed by the presence of maternal fever (temperature ≥37.8°C or ≥38.0°C) plus two or more of the five following clinical signs: maternal tachycardia (heart rate >100 beats/min), fetal tachycardia (heart rate >160 beats/min), uterine tenderness, purulent or foul-smelling amniotic fluid or vaginal discharge, and maternal leukocytosis (white blood cell count >15,000/mm3).
Thus, it appears reasonable to administer ACS to women with clinical chorioamnionitis between 24 0/7 and 33 6/7 weeks of gestation and to consider its administration to those with a gestational age between 23 0/7 and 23 6/7 weeks.
In summary, the current evidence supports the administration of antenatal magnesium sulfate to women with clinical chorioamnionitis between 24 0/7 and 33 6/7 weeks of gestation for preventing cerebral palsy in their offspring.
Once a diagnosis of clinical chorioamnionitis has been established, delivery should be considered, regardless of the gestational age.
Delivery should not be delayed in order to complete the full course of ACS.
View source ↗